NASDAQ: TENXTenax Therapeutics Inc Stock
$3.56+0.06 (+1.71%)
Updated Apr 24, 2024
TENX Price
$3.56
Fair Value Price
N/A
Market Cap
$6.97M
52 Week Low
$3.48
52 Week High
$61.20
P/E
-0.11x
P/B
0.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.44
Operating Cash Flow
-$6M
Beta
0.69
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TENX Overview
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TENX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TENX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TENX is good value based on its book value relative to its share price (0.86x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
TENX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TENX due diligence checks available for Premium users.
Be the first to know about important TENX news, forecast changes, insider trades & much more!
TENX News
Valuation
TENX fair value
Fair Value of TENX stock based on Discounted Cash Flow (DCF)
Price
$3.56
Fair Value
$0.89
Overvalued by
298.08%
TENX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TENX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
15.69x
Market
41.27x
TENX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
5.86x
TENX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TENX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
TENX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.7M
Liabilities
$3.6M
Debt to equity
0.44
TENX's short-term assets ($11.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TENX's short-term assets ($11.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TENX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TENX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
-$174.5k
TENX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TENX vs Biotech Stocks
Tenax Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.